In its latest quarterly filing, Silexion Therapeutics Corp reported ongoing clinical progression of its lead RNAi therapy for KRAS-driven cancers, SIL204, moving closer to Phase 2/3 trials with regulatory approvals in multiple jurisdictions. The company has strengthened manufacturing capabilities via strategic partnerships and raised incremental capital through warrant exercises to fund operations. Despite operational advances, liquidity remains tight with a current ratio of approximately 1, underscoring continued funding dependency. Silexion’s proprietary RNAi platform targeting traditionally undruggable KRAS mutations positions it competitively in a high-unmet-need oncology segment, though clinical and regulatory risks persist. Key milestones include advancing trial enrollment and scaling GMP manufacturing.